The findings suggest that therapeutic strategies aimed at modulating acetate levels or targeting the enzymes involved in acetate metabolism, such as ACSS2, could significantly improve T cell responses and overall efficacy in cancer immunotherapy. This evidence concerns the gene ACSS2 and cancer.